Biotech Pharmaceutical Co., Ltd.
37
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
8.1%
3 terminated/withdrawn out of 37 trials
70.0%
-16.6% vs industry average
27%
10 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (37)
JH013 Injection in Patients With Primary Sjögren's Syndrome
Role: lead
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
Role: lead
A Phase Ia Single Ascending-Dose Study of Subcutaneous EB070 Injection in Healthy Volunteers
Role: lead
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Role: collaborator
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
Role: lead
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Role: lead
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
Role: lead
A Phase I Clinical Trial of JH013 Injection
Role: lead
Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Role: lead
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
Role: collaborator
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Role: lead
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Role: lead
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
Role: lead
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
Role: lead
Safety and Preliminary Clinical Activity of Itolizumab in ARDS
Role: lead
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
Role: lead
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
Role: lead
Safety and Clinical Activity of Itolizumab in aGVHD
Role: lead
Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis
Role: lead
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
Role: lead